About: Regadenoson

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Regadenoson Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008. (en)
http://linked.open...y/drugbank/dosage	http://linked.opendata.cz/resource/drugbank/dosage/271B4A91-363D-11E5-9242-09173F13E4C5
http://linked.open...generalReferences	# Mitka M: New stress test agents reduce adverse effects. JAMA. 2008 May 14;299(18):2140. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18477777 # Lieu HD, Shryock JC, von Mering GO, Gordi T, Blackburn B, Olmsted AW, Belardinelli L, Kerensky RA: Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. J Nucl Cardiol. 2007 Jul;14(4):514-20. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17679059 # Zoghbi GJ, Iskandrian AE: Selective adenosine agonists and myocardial perfusion imaging. J Nucl Cardiol. 2012 Feb;19(1):126-41. doi: 10.1007/s12350-011-9474-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22130964 # FDA label (en)
http://linked.open...gy/drugbank/group	approved (en)
http://linked.open...drugbank/halfLife	Initial phase: 2-4 minutes; Intermediate phase: 30 minutes (this phase coincides with a loss of the pharmacodynamic effect); Terminal phase: 2 hours (en)
http://linked.open...ugbank/indication	Diagnostic agent for radionuclide myocardial perfusion imaging (MPI) (en)
sameAs	Regadenoson
Title	Regadenoson (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB06213/identifier/bindingdb/50119132 http://linked.opendata.cz/resource/drugbank/drug/DB06213/identifier/chemspider/189859 http://linked.opendata.cz/resource/drugbank/drug/DB06213/identifier/drugbank/DB06213 http://linked.opendata.cz/resource/drugbank/drug/DB06213/identifier/kegg-drug/D05711 http://linked.opendata.cz/resource/drugbank/drug/DB06213/identifier/national-drug-code-directory/0469-6501-89 http://linked.opendata.cz/resource/drugbank/drug/DB06213/identifier/pubchem-compound/219024 http://linked.opendata.cz/resource/drugbank/drug/DB06213/identifier/pubchem-substance/47207372 http://linked.opendata.cz/resource/drugbank/drug/DB06213/identifier/wikipedia/Regadenoson
http://linked.open...mechanismOfAction	Regadenoson is an selective low-affinity (Ki= 1.3 µM) A2A receptor agonist that mimics the effects of adenosine in causing coronary vasodilatation and increasing myocardial blood flow. It is a very weak agonist of the A1 adenosine receptor (Ki > 16.5 µM). Furthermore, it has negligible affinity to A2B and A3 adenosine receptors. Regadenoson is undergoing trials for use in pharmacological stress tests. Adenosine slows conduction time through the A-V node, can interrupt the reentry pathways through the A-V node, and can restore normal sinus rhythm in patients with paroxysmal supraventricular tachycardia (PSVT), including PSVT associated with Wolff-Parkinson-White Syndrome. (en)
http://linked.open...y/drugbank/patent	http://linked.opendata.cz/resource/drugbank/patent/6403567
http://linked.open...outeOfElimination	58% of total regadenoson eliminate is via renal excretion (en)
http://linked.open.../drugbank/synonym	Lexiscan (en)
http://linked.open...drugbank/toxicity	The most common (incidence ≥ 5%) adverse reactions to regadenoson are dyspnea, headache, flushing, chest discomfort, dizziness, angina pectoris, chest pain, and nausea. MTD (male, supine position): 20 µg/kg; MTD (male, standing position): 10 µg/kg; (en)
http://linked.open...umeOfDistribution	Central compartment: 11.5 L; Steady state: 78.7 L (en)
foaf:page	http://www.drugs.com/ppa/regadenoson.html http://www.pdrhealth.com/drugs/lexiscan http://www.rxlist.com/cgi/generic/lexiscan.htm
http://linked.open...ugbank/IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B4A96-363D-11E5-9242-09173F13E4C5
http://linked.open...gy/drugbank/InChI	http://linked.opendata.cz/resource/drugbank/property/271B4A9C-363D-11E5-9242-09173F13E4C5
http://linked.open...Molecular-Formula	http://linked.opendata.cz/resource/drugbank/property/271B4A9B-363D-11E5-9242-09173F13E4C5
http://linked.open.../Molecular-Weight	http://linked.opendata.cz/resource/drugbank/property/271B4A98-363D-11E5-9242-09173F13E4C5
http://linked.open...noisotopic-Weight	http://linked.opendata.cz/resource/drugbank/property/271B4A99-363D-11E5-9242-09173F13E4C5
http://linked.open...y/drugbank/SMILES	http://linked.opendata.cz/resource/drugbank/property/271B4A9A-363D-11E5-9242-09173F13E4C5
http://linked.open.../Water-Solubility	http://linked.opendata.cz/resource/drugbank/property/271B4A94-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logP	http://linked.opendata.cz/resource/drugbank/property/271B4A92-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B4A95-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logS	http://linked.opendata.cz/resource/drugbank/property/271B4A93-363D-11E5-9242-09173F13E4C5
http://linked.open...l/drug/hasATCCode	Regadenoson
http://linked.open...nd-Acceptor-Count	http://linked.opendata.cz/resource/drugbank/property/271B4AA2-363D-11E5-9242-09173F13E4C5
http://linked.open...-Bond-Donor-Count	http://linked.opendata.cz/resource/drugbank/property/271B4AA3-363D-11E5-9242-09173F13E4C5
http://linked.open...drugbank/InChIKey	http://linked.opendata.cz/resource/drugbank/property/271B4A9D-363D-11E5-9242-09173F13E4C5
http://linked.open...urface-Area--PSA-	http://linked.opendata.cz/resource/drugbank/property/271B4A9E-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/Polarizability	http://linked.opendata.cz/resource/drugbank/property/271B4AA0-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Refractivity	http://linked.opendata.cz/resource/drugbank/property/271B4A9F-363D-11E5-9242-09173F13E4C5
http://linked.open...atable-Bond-Count	http://linked.opendata.cz/resource/drugbank/property/271B4AA1-363D-11E5-9242-09173F13E4C5
http://linked.open...ugbank/absorption	The pharmacokinetic profile of regadenoson is best described by a 3-compartment model. T max, injection = 1 to 3 minutes; Onset of pharmacodynamic response = 1 to 3 minutes; E max 12.3 ng/mL (en)
http://linked.open.../affectedOrganism	Humans and other mammals (en)
http://linked.open...casRegistryNumber	313348-27-5 (en)
http://linked.open...drugbank/category	(en)
http://linked.open...rugbank/clearance	Average plasma renal clearance = 450 mL/min. As this value is larger than the glomerular filtration rate, this suggests occurrence of renal tubular secretion. (en)
http://linked.open...k/Bioavailability	http://linked.opendata.cz/resource/drugbank/property/271B4AA8-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Ghose-Filter	http://linked.opendata.cz/resource/drugbank/property/271B4AAA-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/MDDR-Like-Rule	http://linked.opendata.cz/resource/drugbank/property/271B4AAB-363D-11E5-9242-09173F13E4C5
http://linked.open...k/Number-of-Rings	http://linked.opendata.cz/resource/drugbank/property/271B4AA7-363D-11E5-9242-09173F13E4C5
http://linked.open...siological-Charge	http://linked.opendata.cz/resource/drugbank/property/271B4AA6-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Rule-of-Five	http://linked.opendata.cz/resource/drugbank/property/271B4AA9-363D-11E5-9242-09173F13E4C5
http://linked.open...tional-IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B4A97-363D-11E5-9242-09173F13E4C5
http://linked.open...strongest-acidic-	http://linked.opendata.cz/resource/drugbank/property/271B4AA4-363D-11E5-9242-09173F13E4C5
http://linked.open...-strongest-basic-	http://linked.opendata.cz/resource/drugbank/property/271B4AA5-363D-11E5-9242-09173F13E4C5

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 58 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software